Iniparib was the first putative PARP inhibitor to commence phase III clinical trials.

[11] Later results showed increased median survival of triple-negative breast cancer patients from 7.7 to 12.2 months.

[12][13][14] In 2009, the FDA began fast-tracking the new drug application of iniparib for triple-negative breast cancer.

[15][16] Iniparib was also studied as a potential chemotherapeutic agent in the fight against malignant glioma, including glioblastoma.

During the 2013 American Society of Clinical Oncology conference, Sanofi disclosed that iniparib failed to help lung-cancer patients in a late-stage trial, prompting the company to end research into the once-promising compound and take a $285 million charge.